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CARDIAC ARREST IN PATtENTS WITHOUT SIGNIFICANT STRUCTURAL 
HEART DISEASE: A MULTlCENTER EXPERIENCE WITH IMPlANTABLE 
CARDIOVERTER-DEFIBRILLATCR THERAPY 
ND. Meissner, RD. Mosteller. R.T. Steinman, M. Akhtar, 0. Cennom, A. 
~pstefn, R. Fogoros, LB. Lfem, F. Marchllnski. R. Myerburg, E. Veltn, C. 
Schuger, M.H. Lehmann, Wayne State Unlverstty/Harper Hospital, Detroit, 
Michigen 
Hollv R. M-f, William Ci. Stevenson, Lynne W. Stevenson, 
Leslie A. Saxon. UCLA School of Medicine, Los Angeles, CA 
We have recently reported a cumufatfve 2-yr sudden card&c death rate of 7% 
and a total mortality rate of 18% amongst 864 patients (pts) in a multicenter 
Investigator&ted database of implantable cardioverter- deffbrfllator (ICD) 
recipients with structural heart disease (SHD). Uttfe Is known about outcome 
after ICD treatment In pts with no or minimal SHD. Hence, we analyzed 
outcome ln 25 resuscitated cardiac arrest (CA) vtctims (due to ventricular 
ffbrillatlon (VF]) with normal metabolic status and QT Intend, no hlstory of 
alcohol or drug abuse, no antlaanhythmic (AA) drugs, mlnlmal or no coronary 
artety disease, EFa 50%, and absence of algniffcantwalf motion abnormality, 
hypertrophy, or vafvular heart disease. These 25 pts (50% male, mean age 
48 yrs, [range 19791) underwent efectrophysiologlc study (EPS) and received 
ICDs At baseline EPS, ventricular tachycardia was induclbfe In 8 pts (24%, 
sustained In 2, nonsustalned In 4) and VF In 4 pts (18%) with the remainder 
being noninducible. In addltlon to thelr ICD, 4 pts (18%) were discharged on 
A4 drugs. The mean follow-up was 28 months (range 184). The cumulative 
Pyr rates of both sudden cardiac death and total card&c mortality were O%, 
wfth an all-cause mortalfty rate of 8%. AJthough 13 pts (52%) experienced 
ICD shocks, these were felt to be ‘approprtate” (pretyncope) In only 2/13 pts 
(15%) and occurred wfthln 1 yr of Implantation. Shocks occurred during 
atrial fibrillation In 1 pt (8%) and In relation to physical exertion In lo/13 
(77%) pts (all asymptomatic and attributed to sinus tachycardia). 
&g&.&f& In resuscitated CA victims (VP) without slgnlficant SHD treated 
with ICD: 
The impact of an&rhythmic drug therapy on survival was 
examined in 367 advanced heart failure pts (LV ejection fraction 
t 0.7) without history of sustained ventricular tachycardia or (0.20 
fibrillation, hospitalized for optimization of hemodynamic therapy, 
and then followed as outpts. 100 pts (27%) were treated with Class 
I antiarrhythmic drugs, 79 (22%) were taking amiodarone, and 188 
(51%) took no antiarrhythmic drugs. All three groups had similar 
LV ejection fraction, 
hemodynamics, and SUDDEN DEATH 
etiologv of heart failure. 
Pts Teceiving anti- 
arrhythmic drugs 
+ 1ooT--Y--- = --- no ant,arrhythmiC 
compared with pts on no 
s 80 -_____ - --- 
; - - -----_amlodarone 
antiarrhythmic drug were 
more likelv to have 
- paroxysmal or chronic 
atria1 fibrillation (26% vs 13%,p =0.002). By Cox
analysis, pulmonary 
capillary wedge pressure-on therapy, atria1 fibrillation and treatment 
with Class I anti-arrhythmic drugs were independent risk factors for 
1) The 2-y prognosis ls excellent (superior to that of pts with SHD). 
2) Asymptomatic exercise-provoked ICD shocks occur frequently. 
3) The occurrence, albeit Infrequent, of ‘appropriate’ ICD shocks suggests 
that selected pts may benefft from ICD therapy. 
sudden death. At -1 year a&aria1 sudden death risk was 
significantly higher i 
compared with amiod 
drug (14%, p = 0.007). I Amiodarone may be the safest 
drug for symptomatic atria1 and nonsustained ventricular 
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N OF PRIMARY AND SECONDARY CARDIAC 
OR SUSTAINED ARDIA TO 
DEA”IW RISK IN LURE. . . m Holly R. Middlekauff, Lynne W. Stevenson, 
Leslie A. Saxol Mary’Woo, Debra Moser. UCLA Medical Center, 
Los Angeles, CA 
Of 452 consecutive advanced heart failure (HF) pts (mean LV 
ejection fraction 20~6%) discharged from hospital following 
tailored HF therapy, 52 (12%) had survived prior altirted cardiac 
arrest (CA) and 16 (3.5%) had prior sustained ventricular 
tachycardia (VT) without CA. In 32 (7%) pts CA was due to a 
primary arrhythmia (P-CA) and subsequent therapy was 
antiarrhythmic drugs (26 pts) and/or automatic defibrillator (4 pts) 
or ablation (2 pts). In 20 (4%) pts (S-CA) CA was secondary to HF 
exacerbation, electrolyte im b?t%nce, or drug induced torsade de 
pointes and subsequent ,,,SUDDEN DEATH RISK 
treatment was to prevent 
inciting factors. E pts 04. S-CA 
were treated with drugs 03. 
(14 pts) and/or defib- ’ ,’ 
rillator (5 pts). One year 0.2: 
P-CA 
, 
actuarial sudden death 
risk was 17% in no-CA, 
o ,, 
I 
21% in P-CA, 39% in S- 
CA and 6% in VT pts (P 
00”------- 100 200 300 400 
DAYS 
= 0.02, S-CA vs no CA). LV ejection fraction and hemodynamics 
were similar in all 4 groups. By Cox analysis S-CA predicted sudden 
death independent of ejection fraction, and hemodynamics. 
: CA due to secondary factors indicates a high sudden 
death risk even after inciting factors are addressed. With current 
therapy pts with hemodynamically tolerated VT have a similar 
sudden death risk to pts with no prior CA and primary arrhythmia 
CA pts may have a slightly increased risk. 
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, Catherine Chelimsky-Fallick, Lynne W. Stevenson, 
William 6. Stevenson, Michael Luu. Michele A Hamilton Jaime 
Moriguchi, Julie A. Walden, Jan Tillisch. UCLA Medical Center, 
lL.43~ Angeles, CA 
Mortality in heart failure has been reduced both by angiotensin- 
ccnverting-enzyme inhibitors (ACEI) and hydralazine/isordil (H/I), 
without obvious effect on sudden death. As these Rx have not 
previously been compared in a randomized trial, we randomized 
106 pts evaluated for transplant (mean EF 20%) to captopril 
(ACEI) or H/I titrated to match hemodynamics achieved on 
nitroprusside and diuretics to approach PCW 15mm and SVR 1200 
d-see-cm”, with oral drug crossover for poor hemodynamics or side 
effects (46% from ACEI, 25% from H/I). Sudden death occurred 
in 3/44 ACEI pts and 18/62 H/I pts (p = .006). Cox analysis howed 
vasodilator drug received to Probrbilily 01 Sudden Daalh 
predict sudden death (p = .004), 1OOs’ 
independently of the only other BoI, 
:%;, 
predictor, low PCW on therapy 
I 
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@=.Ol). Na predicted total @JS, 
mortality but not sudden death. 40~, 
The impact of ACE1 in P’ 
decreasing sudden death was 20%. - .e_ . 
-1 
observed in the 62 pts with Na + rc-c * 
O-006 
- . .-. I 
L 136 (p= .04) as well as in the -o “-.-A;:. -x .- * --2 -- . 6 _ _I 9 12 
44 hyponatremic pts (p=.O4). lrlonlhs 
Compared to H/I titrated to the same hemodynamic goals, ACE1 
reduced sudden death, which has not previously been demonstrated. 
This apparent benefit of ACEI in advanced heart failure was not 
limited to patients with hyponatremia. 
